The Dry Eye Zone

Rebecca's Blog


Drug news: Lux Biosciences projects

How fitting... two new births to make up for two recent deaths... Something is apparently in the works from Lux that we'll know more about from ARVO in April.

Lux Biosciences to Provide Update on Four Pipeline Programs, Including Two Phase 3 Clinical Programs, at ARVO

We also will be presenting highly original work with bioerodible polymers as well as a clear, mixed micellar formulation for ocular delivery of our next generation calcineurin inhibitor (LX212 and LX214, respectively). These latter two product candidates are tailor-made for dry eye and other, highly prevalent chronic inflammatory diseases of the eye.”

Further blurb on LX214:

LX214, a novel topical eye drop formulation currently in IND-enabling studies with a target date for entry into the clinic in mid 2008. LX214 is based on Lux’ proprietary next-generation calcineurin inhibitor and is targeted towards other chronic inflammatory diseases of the eye, most notably dry eye syndrome, blepharitis and atopic keratoconjunctivitis.
Rebecca1 Comment